P&G's ALEVE PROSPERING AT EXPENSE OF NON-TYLENOL ACETAMINOPHEN PRODUCTS
This article was originally published in The Tan Sheet
P&G's ALEVE PROSPERING AT EXPENSE OF NON-TYLENOL ACETAMINOPHEN PRODUCTS, according to Nielsen data. Almost all of Aleve's dollar share of the OTC analgesic market has come from acetaminophen while ibuprofen products' share has held steady through the introduction. However, Nielsen data indicate that the effect on Tylenol brand acetaminophen has been limited, and Aleve has been taking a little share from each of the acetaminophen brands.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC